The Brigham and Dana-Farber Board Review in Hematology and Oncology 2020

228 views CME, Brigham Board Review

The Brigham and Dana-Farber Board Review in Hematology and Oncology

Brigham and Women’s Hospital Board Review

This comprehensive CME program offers an in-depth, case-base review of the clinical essentials in hematology and oncology.

Improve Patient Care in Hematology and Oncology

The Brigham and Dana-Farber Board Review in Hematology and Oncology will help improve clinical practice gaps in hematology and oncology derived from the American Board of Internal Medicine (ABIM) certification/recertification requirements. In this CME program, expert speakers address relevant topics in case-based board review presentations. Improve patient care by learning to:

– Perform differential diagnosis of complex hematologic and oncologic disorders

– Identify and apply current therapeutic options for hematologic and oncologic disorders

– Evaluate and interpret up-to-date literature relevant to hematology and oncology

– Illustrate knowledge of pathophysiology of hematologic and oncologic disorders

– Apply new knowledge to the ABIM certification/recertification hematology and oncology examinations

CHECK SAMPLES

The Brigham and Dana-Farber Board Review in Hematology and Oncology

1

Molecular Genetics of Cancer – Nikhil Wagle, MD

2

Advances in Cancer Drug Development – Geoffrey I. Shapiro, MD, PhD

3

Infections in Cancer Patients – Lindsey Baden, MD

4

Symptom Management in Patients with Cancer – Andrew J. Lawton, MD

5

Communication: The Key to Excellence in End-of-Life Care – Rachelle E. Bernacki, MD

6

Biology of Hematopoietic Stem Cell Transplantation – Robert J. Soiffer, MD

7

Biology of Acute Leukemia and Myelodysplastic Syndromes – Benjamin L. Ebert, MD, PhD

8

Acute Leukemias – Daniel J. DeAngelo, MD, PhD

9

Myelodysplastic Syndrome – David P. Steensma, MD

10

Chronic Myelogenous Leukemia – Marlise R. Luskin, MD

11

Myeloproliferative Syndromes – Ann M. Mullally, MD

12

Multiple Myeloma – Kenneth C. Anderson, MD

13

Waldenstrom Macroglobulemia and Amyloidosis – Jorge J. Castillo, MD

14

Low Grade Lymphomas – Caron A. Jacobson, MD

15

High Grade Lymphomas – Eric D. Jacobsen, MD

16

Hodgkin’s Lymphoma – Jennifer L. Crombie, MD

17

Diagnosis and Treatment of CLL and Related B Cell Malignancies – Matthew S. Davids, MD

18

Head and Neck Cancer – Robert I. Haddad, MD

19

Natural History, Screening, Surgery and Small Cell Lung Cancer – Bruce E. Johnson, MD

20

Non Small Cell Lung Cancer – Mark Awad, MD, PhD

21

Mesothelioma and Thymoma – David M. Jackman, MD

22

Thyroid Cancer – Jochen Lorch, MD

23

Carcinoid and Pancreatic Neuroendocrine Tumors – Jennifer Ang Chan, MD

24

Esophageal and Gastric Cancer – Peter C. Enzinger, MD

25

Pancreatic and Hepatobiliary Cancer – Brian M. Wolpin, MD

26

Anal Cancers – Robert J. Mayer, MD

27

Colorectal Cancers – Robert J. Mayer, MD

28

Gastrointestinal Cancer: Genetic Syndromes – Matthew Yurgelun, MD

29

Germ Cell Tumor: Maximizing Cure While Minimizing the Burden of Therapy – Mark M. Pomerantz, MD

30

Renal and Bladder Cancer – Guru P. Sonpavde, MBBS

31

Prostate Cancer Part I: Overview and Management of Localized Disease – Atish D. Choudhury, MD, PhD

32

Prostate Cancer Part II: Management of Disseminated Prostate Cancer – Atish D. Choudhury, MD, PhD

33

Melanoma – F. Stephen Hodi, MD

34

Sarcomas and Gastrointestinal Stromal Tumors (GIST) – George D. Demetri, MD

35

Ovarian Cancer – Ursula A. Matulonis, MD

36

Cervical and Endometrial Cancer – Panagiotis A. Konstantinopoulos, MD, PhD

37

Neuro-oncology – David A. Reardon, MD

38

Breast Cancer: Risk Factors, Genetics, Screening, and Prevention – Judy E. Garber, MD, MPH

39

Multimodality Therapy for Early Stage Breast Cancer: Part 1 – Surgery and Radiation – Harold J. Burstein, MD, PhD

40

Multimodality Therapy for Early Stage Breast Cancer: Part 2 – Systemic Therapy – Harold J. Burstein, MD, PhD

41

Management of Metastatic Breast Cancer – Erica Mayer, MD, MPH

42

Breast Cancer Survivorship – Ann H. Partridge, MD, MPH

43

Hematopoiesis and Cytokines – David T. Scadden, MD

44

Acquired Bone Marrow Failure – Julie-Aurore Losman, MD, PhD

45

Congenital Bone Marrow Failure – Akiko Shimamura, MD, PhD

46

Hemophagocytic Syndromes and Related Immunodeficiencies – Barbara A. Degar, MD

47

Anemia: An Overview – Ronald P. McCaffrey, MD

48

Iron Deficiency and Iron Overload – Mark D. Fleming, MD, PhD

49

Immune Hemolytic Anemia – Richard M. Kaufman, MD

50

Non-immune Hemolytic Anemia – David E. Golan, PhD, MD

51

Sickle Cell Disease – Maureen M. Achebe, MD, MPH

52

Thalassemia and Other Hemoglobinopathies – Matthew M. Heeney, MD

53

Disorders of Neutrophils – Nancy Berliner, MD

54

Acquired Thrombocytopenias – Elisabeth M. Battinelli, MD, PhD

55

Hemophilia – Aric D. Parnes, MD

56

Von Willebrand Disease and Congenital Platelet Disorders – Nathan T. Connell, MD, MPH

57

Congenital and Acquired Thrombophilia – Kenneth A. Bauer, MD

58

Use of Direct Oral Anticoagulants in Clinical Practice – Jean M. Connors, MD

59

Transfusion Medicine for the Clinician – Walter H. Dzik, MD

Learning Objectives

At the conclusion of this activity, the participant will be able to:

– Apply current/recommended Hematology and Oncology guidelines in clinical practice

– Perform differential diagnosis of complex clinical presentations related to Hematologic and Oncologic disorders

– Identify/apply current therapeutic options for specific Hematologic and Oncologic disorders

– Review and interpret up-to-date literature relevant to clinical practice in Hematology and Oncology

– Demonstrate knowledge of pathophysiology as it applies to management of Hematology and Oncology disorders

– Apply knowledge gained to the ABIM Certification/Recertification Hematology and Oncology examinations

Intended Audience

The activity was planned for fellows/trainees, practicing Hematology and Oncology specialists (MDs), and other professional affiliates (internists with an interest in Hematology and Oncology) who are preparing to take ABIM Board Review or Recertification Examinations, or who seek CME activities to improve patient care in the areas of Hematology and Oncology Medicine.

Designation

Date of Original Release: April 15, 2020

Date of Original Release: April 15, 2023

Subscribe
Notify of
guest
2 Comments
Newest Oldest
Inline Feedbacks
View all comments
A A
A A
03/05/2020 10:36

How many people have signed up so far ?

error: Content is protected !!